Hamburg, Germany

Rita Blankenburg


 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rita Blankenburg: Innovator in Pharmaceutical Composition

Introduction

Rita Blankenburg is a notable inventor based in Hamburg, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of semisolid preparations for various medical conditions. Her innovative work has led to the creation of a patent that addresses critical health issues.

Latest Patents

Rita Blankenburg holds a patent for the "Use of octenidine dihydrochloride in semisolid preparations." This invention relates to the use of octenidine dihydrochloride for manufacturing a semisolid pharmaceutical composition aimed at treating wounds, atopic dermatitides, infected eczemas, dermatomycoses, vaginal infections, acne, herpes, and controlling multidrug-resistant pathogens. The composition comprises from 0.005 to 5% by weight of octenidine dihydrochloride, showcasing her commitment to advancing medical treatments.

Career Highlights

Throughout her career, Rita has worked with prominent companies in the pharmaceutical industry. She has been associated with Air Liquide Santé, an international company, and Schülke & Mayr GmbH, where she has contributed her expertise in pharmaceutical innovations. Her work has been instrumental in developing effective treatments for various health conditions.

Collaborations

Rita has collaborated with notable professionals in her field, including Jorg Siebert and Mona Golombiewski. These collaborations have further enhanced her research and development efforts, leading to impactful innovations in pharmaceutical compositions.

Conclusion

Rita Blankenburg is a pioneering inventor whose work in pharmaceutical compositions has made a significant impact on healthcare. Her patent for the use of octenidine dihydrochloride exemplifies her dedication to improving treatment options for patients. Through her career and collaborations, she continues to contribute to advancements in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…